The Food and Drug Administration yesterday alerted health care professionals and patients not to use drug products produced by Cantrell Drug Co., including opioid products and other drugs intended for sterile injection, citing serious deficiencies in the company’s compounding operations. “Despite the FDA’s concerns about egregious conditions observed at Cantrell’s facility, during several inspections, with the most recent in 2017, the company continued to compound and distribute drugs without adequately addressing their potentially dangerous conditions,” said FDA Commissioner Scott Gottlieb, M.D. “This reckless activity threatens patient safety and will not be tolerated.” FDA has sought legal action to prevent the company from further producing and distributing drugs. It said health care professionals should immediately check their medical supplies, quarantine any drug products from the company and not administer them to patients. The agency is not aware of illness reports associated with the products, but asks health care professionals to report any associated adverse events or quality problems to its MedWatch program.

Related News Articles

Headline
Beginning with open enrollment for plan year 2020, the Centers for Medicare…
Headline
Currently available public hospital quality rating systems frequently offer conflicting results, which may mislead stakeholders relying on the ratings to…
Headline
The Centers for Disease Control and Prevention has released the first in a new series of free online training courses to help health care organizations prevent…
Headline
Patients receiving either of two investigational treatments for Ebola in the Democratic Republic of the Congo had a greater chance of survival than those…
Chairperson's File
Often quietly and out of the public eye, the vital work of advancing health in America happens on many fronts.
Headline
The Department of Health and Human Services offers a resource to help health care providers and others prepare for and respond to mass violence events such as…